EGFR and non-small cell lung carcinoma: A meta-analysis including 24 studies with 2,227 patients with EGFR-mutated NSCLC found that patients with TP53-EGFR co-mutations had significantly shorter PFS and overall survival (OS) duration compared to those with wild-type TP53 (23).